Trellis Bioscience LLC
Overview
Trellis Bioscience LLC develops human monoclonal antibodies (mAbs) for the treatment of infectious diseases and cancer, leveraging its proprietary CellSpot™ platform for discovery. The company is conducting clinical trials for its lead product, TRL1068, aimed at treating prosthetic joint infections.
Therapeutic areas
FDA compliance signals
No FDA recalls, Warning Letters, or Form 483 observations are linked to Trellis Bioscience LLC in our records. PharmaTek screens the full directory against live FDA enforcement data.
Related companies
454 Life Sciences Corporation
United States
ABC Health Research Institute
USA
AC Biotech Incorporated
USA
Aequita Bioworks Inc.
United States
AGC Biopharma, Inc.
USA
American Cyanamid Company (as Wyeth-Ayerst Laboratories)
United States
AS Pharmaceutical Inc.
USA
Ascendia Pharmaceutical Solutions, Inc.
United States
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.